Tunlametinib
- Generic Name
- Tunlametinib
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
适用含抗PD-1/PD-L1治疗失败的NRAS突变的晚期黑色素瘤、结直肠癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06008106
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath